Last time Chip sold, there were stellar recurrent news 2 months later. So, maybe we will receive fantastic news in mid August.
This time, 6 others bought while Chip sold.
4Q15 - Rindo Pdufa
4Q16 - Primary Completion Glemba
4Q17 - Primary Completion Varli
2.5 years of max price appreciation.
After recurrence, tail looks like 20% chance of long term survival of many years just like the other three Phase 2 trials.
It seems probable that if the balance regarding the post surgery patients were distributed evenly to the non-rindo patients, efficacy would have improved for Rindo. Thats something CLDX will need to show FDA.
With front line, Recurrence is further reduced.
Sure, lets not give v3 patients no hope for long term survival by not approving rindo.
Profit taking on their long position drove prices lower to maximize their profit taking on the short position. Just give it time
Tutes own the long shares
Tutes own the short positions
Tutes sold to cover their short positions, trigger sells, and increase long position
Just answer this one question.
Q: What is the stock price when institutions own the vast majority of shares?
A: Whatever they want it to be.
Just be patient. They will cover and let it rise when they are ready. Wednesday.
End of 2015 - $50
End of 2016 - $100
End of 2017 - $150
End of 2018 - $200
End of 2019 - $250
Acquisition Price will be perpetually 100% above market.
1. Bristol, 2. Roche, 3. Every other pharmaceutical or biotech companies will be the possible suitors
Premiums are easier to swallow when using premium priced stock to trade for acquisition. $10 billion is easy to swallow for either desperate pharmas or premium priced biotechs.
IMHO good luck
Rindo alone turns CLDX into a GEVA. Same max revenues potential. I believe we are 4-6 months behind them.
The simple questions is.....what price institutions want when they own 99% considering they can control daily price at that point?
End of 2017, Rindo on market, Glemba PDUFA, and Varli Results.....
If varli results are similar to pre-clinical, then all bets are off.
Agreed. Technicals are catching up, tutes are covering their short position and taking ownership to 99.99% right before the ASCO news. Lets see what happens when buy orders of 10 million shares clamor for the remaining 100K shares.
The final destination is already set with BMY or Roche.
Chess pieces are moving into place one piece at a time.
Van De Broek is building the Institutional rocket ship.
Retail is in the luggage rack hitching a ride...